Boehringer Ingelheim

Works in Cardiovascular · Dermatology · Genetic & rare · GI & liver · Hematology · Immunology · Infectious disease · Metabolic & endocrine · Musculoskeletal · Neurology · Oncology · Ophthalmology · Psychiatry · Renal & urogenital · Respiratory · Women's health

Boehringer Ingelheim is a clinical trial sponsor. It has 96 active clinical trials with 637,697 planned participants, across 16 therapeutic areas. Since 2021 it has completed 539 trials and stopped 93 early.

Trial track record · since 2021

96Active trials637,697 planned participants
539Completed432 with results posted
93Stopped early15% of finished trials

Pipeline · 96 active trials

StageTrialStatus

On the market

28 approved drug applications with a product on the market.

Questions about Boehringer Ingelheim

See the rest of this profile

A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.

Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-11-05.

Approve Suite is not affiliated with Boehringer Ingelheim.

See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.